GlassScriptPhysician profile
Coca Anghelache
NPI 1306170923
$2,942.23
in general payments reported to CMS, 2019-2025
32 companies · $642 in 2025
The $642 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $582 · 2022: $537 · 2023: $680 · 2024: $501 · 2025: $642.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,678 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,677.99 |
| Education | $144.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $607.54 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $315.76 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $223.14 | 2021-2024 | Xarelto |
| Mylan Specialty L.P. | $178.60 | 2023-2024 | Yupelri, Yupelri |
| Astellas Pharma US INC | $163.55 | 2022-2023 | Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $138.33 | 2022-2025 | Austedo Xr, Austedo Xr |
| Urovant Sciences INC | $120.41 | 2021-2022 | |
| Lilly USA, LLC | $115.22 | 2021-2025 | Kisunla, Emgality, Jardiance |
| Novartis Pharmaceuticals Corporation | $93.23 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $80.42 | 2022 | |
| Neurocrine Biosciences, INC. | $77.10 | 2022 | |
| Idorsia Pharmaceuticals US INC | $76.50 | 2023 | Quviviq |
| Sumitomo Pharma America, INC. | $76.31 | 2023-2025 | Gemtesa |
| Pfizer INC. | $75.40 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $66.71 | 2022-2025 | Gardasil 9, Capvaxive |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $55.80 | 2024 | |
| Alpha Cognition USA, INC. | $50.54 | 2025 | Zunveyl |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.32 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $46.53 | 2023-2024 | Nuedexta, Rexulti |
| Abiomed | $40.78 | 2024 | Impella |
| Abbvie INC. | $37.96 | 2025 | |
| Nestle Healthcare Nutrition INC. | $37.87 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $34.87 | 2023-2024 | |
| Amarin Pharma, INC. | $29.53 | 2021 | |
| Novo Nordisk INC | $25.36 | 2022-2023 | Wegovy |
| Biohaven Pharmaceuticals, INC. | $20.73 | 2021 | |
| Esperion Therapeutics, INC. | $19.88 | 2025 | Nexletol |
| Glaxosmithkline, LLC. | $19.61 | 2021 | |
| Amgen INC. | $18.12 | 2024 | Prolia, Evenity |
| Exact Sciences Corporation | $17.08 | 2024 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $16.18 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.85 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Coca Anghelache listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.